Clinical Outcomes in Patients With Cirrhosis Following TAVR

Although most other clinical outcomes are similar, readmission rates are higher in patients with cirrhosis compared with patients without cirrhosis following transcatheter aortic valve replacement (TAVR). These findings were presented at the American College of Cardiology (ACC) 2023 Conference, held from March 4 to 6, 2023, in New Orleans, Louisiana.

Between 2012 and 2019, the National Readmission Database was explored for International Classification of Diseases, Tenth Revision (ICD-10) codes that had been used to identify patients with TAVR. The population obtained was divided into 2 groups, patients with cirrhosis receiving TAVR and patients without cirrhosis receiving TAVR. Chi-square statistics in software Stata v.17 were utilized to evaluate cardiovascular outcomes in both of the cohorts at index admission.

From 2012 to 2019, a total of 308,802 individuals who had received TAVR were identified. Overall, 1.74% of these patients had cirrhosis and 98.3% did not have cirrhosis. The mean patient age was 71.6 years in individuals with cirrhosis and 79.9 years in those without cirrhosis.

Results of the study demonstrated that the prevalence of coagulopathy (55.7%), uncomplicated diabetes (38.4%), fluid and electrolyte disorders (34.5%), and anemia (30.7%) was significantly higher among the group of patients who had received TAVR with cirrhosis compared with those who had received the procedure and did not have cirrhosis (P <.05 for all).  Further, hospital readmission rates at 30 days, 90 days, and 180 days were significantly higher among patients in the TAVR-with-cirrhosis group than in those in the TAVR-without-cirrhosis group (P <.05).

“Outcomes were similar in both TAVR patients with cirrhosis and without cirrhosis,” the study authors wrote. “However, readmission rates were high in TAVR patients with cirrhosis.”